Distinguish the Regulatory Expectations Regarding Post-Emergency Situations & Impact on Quality Control for the Streamline of Your mRNA Therapeutics

Time: 9:31 am
day: Pre-Conference Day


In recent years, mRNA-based therapies have shown remarkable promise in treating a wide range of diseases, from cancer to genetic disorders. However, one of the key challenges in realizing the full potential of these therapies lies in efficient regulatory guidelines. This workshop offers a deep dive into the evolving regulatory landscape surrounding mRNA therapeutics and its consequential impact on quality control practices. Participants will engage in lessons learned from mRNA in the COVID-19 era.

Join this session to discuss:

  • How has the regulatory landscape evolved post-emergency situations, focusing on changes in expectations for mRNA quality control and compliance
  • What are the strategies adopted by organizations to meet evolving requirements
  • How can we use lessons learned and apply this to future vaccine and therapeutic development